James Fisher

Jan 4, 2024 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |Julian F.R. Paton |James Fisher

To the Editor:Impairment of exercise capacity, predominantly limited symptomatically by dyspnoea [1], affects most patients with pulmonary arterial hypertension (PAH) despite current therapies [2], with significant implication for patients, adversely impairing health-related quality of life [3] and clinical prognosis [4]. However, the underpinning physiological mechanisms behind dyspnoea and exercise limitation remain incompletely understood.

Sep 7, 2023 | erj.ersjournals.com | Michael Plunkett |Tanya J McWilliams |James Fisher

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Received June 6, 2023. Accepted August 17, 2023.

Mar 14, 2023 | agcc.co.uk | James Fisher

James Fisher and Sons plc (‘James Fisher’, ‘the Group’) announces the appointment of Rob Hales as Head of Defence with responsibility for directing and overseeing the Group’s global defence division operations and growth. In this capacity, Rob sits on the James Fisher executive team and reports to Chief Executive Officer, Jean Vernet.